Antibodies and Biomarkers in Cardio-Rheumatology

Villa-Forte A, Mandell BF. Cardiovascular disorders and rheumatic disease. Rev Española Cardiol. 2011;64(9):809–17.

Mendez-Rayo T, Ochoa-Zárate L, Posso-Osorio I, et al. Interpretation of autoantibodies in rheumatological diseases. Rev Colomb Reumatol. 2018;25(2):112–25.

Hamaguchi Y, Takehara K. Anti-nuclear autoantibodies in systemic sclerosis: News and perspectives. J Scleroderma Relat Disord. 2018;3(3):201–13.

Zuo Y, Navaz S, Liang W, et al. Prevalence of antiphospholipid antibodies and association with incident cardiovascular events. JAMA Netw open. 2023;6(4):e236530.

Meier LA, Binstadt BA. The contribution of autoantibodies to inflammatory cardiovascular pathology. Front Immunol. 2018;9:911.

Odler B, Foris V, Gungl A, et al. Biomarkers for pulmonary vascular remodeling in systemic sclerosis: A pathophysiological approach. Front Physiol. 2018;9:587.

Laterza OF, Nayer H, Jo Bill M, Sokoll LJ. Unusually high concentrations of cTnI and cTnT in a patient with catastrophic antiphospholipid antibody syndrome. Clin Chim Acta. 2003;337(1–2):173–6.

Watad A, McGonagle D, Bragazzi NL, et al. Systemic sclerosis is an independent risk factor for ischemic heart disease, especially in patients carrying certain antiphospholipid antibodies: A large cross-sectional study. Eur J Intern Med. 2020;81:44–9.

Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. New Engl J Med. 2009;360(19):1989–2003.

Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol. 2015;6:272.

Ali RA, Halabi H, Almoallim H. Cardiovascular diseases and rheumatology. Ski Rheumatol. 2021;353–81.

Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.

Janosik DL, Osborn TG, Moore TL, et al. Heart disease in systemic sclerosis. Semin Arthritis Rheum. 1989;19(3):191–200.

Cavazzana I, Vojinovic T, Airo’ P, et al. Systemic sclerosis-specific antibodies: Novel and classical biomarkers. Clin Rev Allergy Immunol. 2023;64(3):412–30.

Bruni C, Ross L. Cardiac involvement in systemic sclerosis: Getting to the heart of the matter. Best Pract Res Clin Rheumatol. 2021;35(3):101668.

Campochiaro C, De Luca G, De Santis M. Anti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis. Ann Rheum Dis. 2021;80(7):E113.

Caforio ALP, De Luca G, Baritussio A, et al. Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates. Diagnostics (Basel). 2021;11(11):2165.

Lee JJ, Pope JE. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435.

Hinchcliff M, Khanna S, Hsu VM, et al. Survival in systemic sclerosis-pulmonary arterial hypertension assessment and recognition of outcomes in scleroderma (PHAROS) registry. Semin Arthritis Rheum. 2016;45(3):309–14.

Ishii Y, Fujii H, Sugimura K, et al. Successful treatment of pulmonary arterial hypertension in systemic sclerosis with anticentriole antibody. Case Rep Rheumatol. 2020;2020:1926908.

Hamaguchi Y, Matsushita T, Hasegawa M, et al. High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies. Mod Rheumatol. 2015;25(5):798–801.

Almoallim H, Cheikh M. Skills in rheumatology. Singapore: Springer; 2021.1–566 p.

Nowakowska-Płaza A, Wroński J, Werońska-Tatara J, et al. Heart disease in the course of systemic sclerosis - an observational study. Reumatologia. 2022;60(5):318–25.

Mitev A, Christ L, Feldmann D, et al. Inflammatory stays inflammatory: a subgroup of systemic sclerosis characterized by high morbidity and inflammatory resistance to cyclophosphamide. Arthritis Res Ther. 2019;21(1):262.

Jung E, Suh CH, Kim HA, Jung JY. Clinical characteristics of systemic sclerosis with interstitial lung disease. Arch Rheumatol. 2018;33(3):322–7.

Kiatchoosakun S, Ungkasekvinai W, Wonvipaporn C, et al. D-dimer and pulmonary arterial hypertension in systemic sclerosis. J Med Assoc Thail. 2007;90(10):2024–9.

George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res. 2014;114(4):677–88.

Van Bon L, Affandi AJ, Broen J, et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med. 2014;370(5):433–43.

Pendergrass SA, Hayes E, Farina G, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One. 2010;5(8):e12106.

Christmann RB, Hayes E, Pendergrass S, et al. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Rheum. 2011;63(6):1718–28.

Nakamura K, Asano Y, Taniguchi T, et al. Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis. J Dermatol. 2016;43(8):912–8.

Stefanantoni K, Sciarra I, Vasile M, et al. Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor b in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Reumatismo. 2015;66(4):270–6.

Meadows CA, Risbano MG, Zhang L, et al. Increased expression of growth differentiation factor-15 in systemic sclerosis-associated pulmonary arterial hypertension. Chest. 2011;139(5):994–1002.

Shirai Y, Okazaki Y, Inoue Y, et al. Elevated levels of pentraxin 3 in systemic sclerosis: Associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol. 2015;67(2):498–507.

Rusnati M, Camozzi M, Moroni E, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood. 2004;104(1):92–9.

Avouac J, Guignabert C, Hoffmann-Vold AM, et al. Role of stromelysin 2 (Matrix Metalloproteinase 10), a novel mediator of vascular remodeling underlying pulmonary hypertension associated with systemic sclerosis. J Scleroderma Relat Disord. 2017;69(11):2209-2221.

Lorenzen JM, Krämer R, Meier M, et al. Osteopontin in the development of systemic sclerosis-relation to disease activity and organ manifestation. Rheumatology. 2010;49(10):1989–91.

Elias GJ, Ioannis M, Theodora P, et al. Circulating tissue inhibitor of matrix metalloproteinase-4 (TIMP-4) in systemic sclerosis patients with elevated pulmonary arterial pressure. Mediators Inflamm. 2008;2008:164134.

Kawashiri SY, Ueki Y, Terada K, et al. Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. Rheumatol Int. 2014;34(2):221–5.

Ciurzynski M, Bienias P, Irzyk K, et al. Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol. 2014;33(1):83-9.

Foris V, Kovacs G, Marsh LM, et al. CD133+ cells in pulmonary arterial hypertension. Eur Respir J. 2016;48(2):459–69.

Toshner M, Voswinckel R, Southwood M, et al. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2009;180(8):780–7.

Nevskaya T, Bykovskaia S, Lyssuk E, et al. Circulating endothelial progenitor cells in systemic sclerosis: Relation to impaired angiogenesis and cardiovascular manifestations. Clin Exp Rheumatol. 2008;26(3):421–9.

Thakkar V, Stevens W, Prior D, et al. The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: A case control study. Clin Exp Rheumatol. 2016;34:129–36.

Dağ Ş, Budulgan M, Dilek B, et al. Relation of asymmetric dimethylarginine and cardiac involvement in systemic sclerosis. Acta Reumatol Port. 2014;39(3):228–35.

Dimitroulas T, Giannakoulas G, Sfetsios T, et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology. 2008;47(11):1682–5.

Papaioannou AI, Zakynthinos E, Kostikas K, et al. Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis. BMC Pulm Med. 2009;9:18.

Reiseter S, Molberg Ø, Gunnarsson R, et al. Associations between circulating endostatin levels and vascular organ damage in systemic sclerosis and mixed connective tissue disease: An observational study. Arthritis Res Ther. 2015;17(1):231.

Riccieri V, Stefanantoni K, Vasile M, et al. Abnormal plasma levels of different angiogenic molecules are associated with different clinical manifestations in patients with systemic sclerosis. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S46-52.

Coral-Alvarado P, Quintana G, Garces MF, et al. Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis. Rheumatol Int. 2009 Jul;29(9):1017-24.

Wermuth PJ, Piera-Velazquez S, Jimenez SA. Exosomes isolated from serum of systemic sclerosis patients display alterations in their content of profibrotic and antifibrotic microRNA and induce a profibrotic phenotype in cultured normal dermal fibroblasts. Clin Exp Rheumatol. 2017;35:S21–30.

Nakamura K, Jinnin M, Harada M, et al. Altered expressionof CD63 and exosomes in scleroderma dermal fibroblasts. J Dermatol Sci. 2016;84(1):30-39.

Zhao Y, Ponnusamy M, Zhang L, et al. The role of miR-214 in cardiovascular diseases. Eur J Pharmacol. 2017;816:138–45.

Wei C, Henderson H, Spradley C, et al. Circulating miRNAs as potential marker for pulmonary hypertension. PLoS One. 2013;8(5):e64396.

Izumiya Y, Jinnn M, Kimura Y, et al. Expression of Let-7 family microRNAs in skin correlates negatively with severity of pulmonary hypertension in patients with systemic scleroderma. IJC Hear Vasc. 2015;8:98–102.

Allanore Y, Borderie D, Avouac J, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008;58(1):284–91.

Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (NTproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006;27(12):1485–94.

Yu H, Nagafuchi Y, Fujio K. Clinical and immunological biomarkers for systemic lupus erythematosus. Biomolecules. 2021;11(7):928.

Guzmán-Martínez G, Marañón C. Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers. Front Immunol. 2022;13:974826.

Ruiz D, Oates JC, Kamen DL. Antiphospholipid antibodies and heart valve disease in systemic lupus erythematosus. Am J Med Sci. 2018;355(3):293–8.

Dabit JY, Valenzuela-Almada MO, Vallejo-Ramos S, Duarte-García A. Epidemiology of antiphospholipid syndrome in the general population. Curr Rheumatol Rep. 2021;23(12):85.

Dhakal BP, Kim CH, Al-Kindi SG, Oliveira GH. Heart failure in systemic lupus erythematosus. Trends Cardiovasc Med. 2018;28(3):187–97.

López P, Rodríguez-Carrio J, Martínez-Zapico A, et al. Serum levels of anti-PON1 and anti-HDL antibodies as potential biomarkers of premature atherosclerosis in systemic lupus erythematosus. Thromb Haemost. 2017;117(11):2194–206.

Domingues V, Magder LS, Petri M. Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med. 2016;3(1):e000107.

Choe JY, Lee SS, Kwak SG, Kim SK. Anti-Sm antibody, damage index, and corticosteroid use are associated with cardiac involvement in systemic lupus erythematosus: Data from a prospective registry study. J Korean Med Sci. 2020;35(21):e139.

Arroyo-Ávila M, Santiago-Casas Y, McGwin G, et al. Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. Clin Rheumatol. 2015;34(7):1217–23.

Du Toit R, Karamchand S, Doubell AF, et al. Lupus myocarditis: review of current diagnostic modalities and their application in clinical practice. Rheumatol (United Kingdom). 2023;62(2):523–34.

Zuily S, Regnault V, Selton-Suty C, et al. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: Meta-analysis of echocardiographic studies. Circulation. 2011;124(2):215–24.

Mattos P, Santiago MB. Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: A systematic review. Clin Rheumatol. 2011;30(2):165–71.

Kolitz T, Shiber S, Sharabi I, et al. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019;10:941.

Buleu F, Sirbu E, Caraba A, Dragan S. Heart involvement in inflammatory rheumatic diseases: A systematic literature review. Med. 2019;55(6):249.

Plazak W, Gryga K, Milewski M, et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus. 2011;20(9):936–44.

Casian M, Jurcut C, Dima A, et al. Cardiovascular disease in primary Sjögren’s Syndrome: Raising clinicians’ awareness. Front Immunol. 2022;13:865373.

Higuera-Ortiz V, Mora-Arias T, Castillo-Martinez D, Amezcua-Guerra LM. Anti-Ro/SSA antibodies are associated with severe mitral valve regurgitation in patients with systemic lupus erythematosus. Mod Rheumatol. 2017;27(3):476–80.

Mei YJ, Wang P, Jiang C, et al. Clinical and serological associations of anti-ribosomal P0 protein antibodies in systemic lupus erythematosus. Clin Rheumatol. 2018;37(3):703–7.

Melano-Carranza E, Zambrano-Zambrano A, Valle-Uitzil W, et al. Coronary artery disease in systemic lupus erythematosus: What Do the Facts Say? Cureus. 2023;15(1):e33449.

Sahebkar A, Rathouska J, Derosa G, et al. Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmun Rev. 2016;15(4):344–53.

Mok CC, Wong CK, To CH, et al. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Arthritis Care Res. 2011;63(6):875–83.

Dima A, Opris D, Jurcut C, Baicus C. Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? Lupus. 2016;25(11):1173–9.

Connelly MA, Otvos JD, Shalaurova I, et al. GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk. J Transl Med. 2017;15(1):219.

Wu H, Birmingham DJ, Rovin B, et al. D-dimer level and the risk for thrombosis in systemic lupus erythematosus. Clin J Am Soc Nephrol. 2008;3(6):1628–36.

Agmon-Levin N, Rosário C, Katz BSP, et al. Ferritin in the antiphospholipid syndrome and its catastrophic variant (cAPS). Lupus. 2013;22(13):1327–35.

Kim SY, Yu M, Morin EE, et al. High-density lipoprotein in lupus: Disease biomarkers and potential therapeutic strategy. Arthritis Rheumatol. 2020;72(1):20–30.

Garcia-de los Ríos C, Medina-Casado M, Díaz-Chamorro A, et al. Sclerostin as a biomarker of cardiovascular risk in women with systemic lupus erythematosus. Sci Rep. 2022;12(1):21621.

López P, Rodríguez-Carrio J, Martínez-Zapico A, et al. Low-density granulocytes and monocytes as biomarkers of cardiovascular risk in systemic lupus erythematosus. Rheumatol (United Kingdom). 2020;59(7):1752–64.

Skeoch S, Haque S, Pemberton P, Bruce IN. Cell adhesion molecules as potential biomarkers of nephritis, damage and accelerated atherosclerosis in patients with SLE. Lupus. 2014;23(8):819–24.

Wu H, Zeng J, Yin J, et al. Organ-specific biomarkers in lupus. Autoimmun Rev. 2017;16(4):391–7.

Chezel J, Costedoat-Chalumeau N, Laouénan C, et al. Highly sensitive serum cardiac troponin T and cardiovascular events in patients with systemic lupus erythematosus (TROPOPLUS study). Rheumatol (United Kingdom). 2021;60(3):1210–5.

Kadoglou NPE, Dimopoulou A, Gkougkoudi E, Parperis K. Altered arterial stiffness, ventricular–arterial coupling and troponin levels in patients with systemic lupus erythematosus. Medicina (Kaunas). 2024;60(5):821.

Tselios K, Gladman DD, Harvey P, et al. Abnormal cardiac biomarkers in patients with systemic lupus erythematosus and no prior heart disease: A consequence of antimalarials? J Rheumatol. 2019;46(1):64–9.

Karadag O, Calguneri M, Yavuz B, et al. B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: What is the clinical significance? Clin Rheumatol. 2007;26(10):1701–4.

Zhang J, Li C, Han X, et al. The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies. Ann Med. 2021;53(1):1328–39.

Stepien K, Nowak K, Wypasek E, et al. High prevalence of inherited thrombophilia and antiphospholipid syndrome in myocardial infarction with non-obstructive coronary arteries: Comparison with cryptogenic stroke. Int J Cardiol. 2019;290:1–6.

Mavrogeni SI, Markousis-Mavrogenis G, Karapanagiotou O, et al. Silent myocardial perfusion abnormalities detected by stress cardiovascular magnetic resonance in antiphospholipid syndrome: A case-control study. J Clin Med. 2019;8(7):1084.

Fu M, Chang S, Ma J, Ge J. A case of repeated in-stent restenosis of coronary artery as a primary manifestation of seronegative antiphospholipid antibody syndrome. BMC Cardiovasc Disord. 2024;24(1):32.

Pinto V, Ministro A, Carreira NR, et al. A catastrophic seronegative anti-phospholipid syndrome: case and literature review. Thromb J. 2021;19(1):103.

Endara SA, Dávalos GA, Fierro CH, et al. Antiphospholipid syndrome and valvular heart disease, a complex scenario of thrombotic events, a case report. J Cardiothorac Surg. 2020;15(1):275.

Ural K, Edelson J. Antiphospholipid syndrome and cardiac bypass: The careful balance between clotting and bleeding. J Extra Corpor Technol. 2021;53(1):46–9.

Petri MA. Classification criteria for antiphospholipid syndrome: The case for cardiac valvular disease. J Rheumatol. 2004;31(12):2329–30.

Erdozain JG, Ruiz-Irastorza G, Segura MI, et al. Cardiac valve replacement in patients with antiphospholipid syndrome. Arthritis Care Res. 2012;64(8):1256–60.

Berkun Y, Elami A, Meir K, et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg. 2004;127(2):414–20.

Colli A, Mestres CA, Espinosa G, et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardio-thoracic Surg. 2010;37(1):154–8.

Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardio-thoracic Surg. 2008;33(2):168–81.

Tarzia V, Tessari C, Fabozzo A, et al. Antiphospholipid antibody syndrome and LVAD: What are the chances? A case report and literature review. Int J Artif Organs. 2022;45(2):235–8.

Bitsadze V, Yakubova F, Khizroeva J, et al. Catastrophic antiphospholipid syndrome. Int J Mol Sci. 2024;25(1):668.

Meyer AL, Kuehn C, Gras C, et al. Implantation of a left ventricular assist device in a patient with primary antiphospholipid syndrome. Ann Thorac Surg. 2008;86(2):639–40.

Zuo Y, Shi H, Li C, Knight JS. Antiphospholipid syndrome: A clinical perspective. Chin Med J (Engl). 2020;133(8):929–40.

Pignatelli P, Ettorre E, Menichelli D, et al. Seronegative antiphospholipid syndrome: Refining the value of “non-criteria” antibodies for diagnosis and clinical management. Haematologica. 2020;105(3):562–72.

Rosen K, Raanani E, Kogan A, et al. Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management. J Hear Lung Transplant. 2022;41(2):208–16.

Kearon C, Parpia S, Spencer FA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19):2151–60.

Karan A, Adeyemo A, Omar M, et al. The lupus attack: A case report and literature review of myocardial infarction and antiphospholipid syndrome. Cureus. 2022;14(4):12–5.

Sciascia S, Cecchi I, Radin M, et al. IgG anti-high-density lipoproteins antibodies discriminate between arterial andvenouseventsinthromboticantiphospholipid syndromepatients. Front Med (Lausanne). 2019;6:211.

Shi M, Gao W, Jin Y, et al. Antiphospholipid syndrome-related pulmonary embolism: clinical characteristics and early recognition. Front Cardiovasc Med. 2022;9:872523.

Eviatar T, Niznik S, Elkayam O, et al. Heart valve surgery in antiphospholipid syndrome patients—morbidity and mortality. Life (Basel). 2023;13(4):891.

Farrukh L, Mumtaz A, Wajid S, et al. Cardiac manifestations of Sjogren’s syndrome: A review of literature. Cureus. 2023;15(6):e41002.

Santos CS, Salgueiro RR, Morales CM, et al. Risk factors for cardiovascular disease in primary Sjögren’s syndrome (pSS): a 20-year follow-up study. Clin Rheumatol. 2023;42(11):3021–31.

Valim V, Gerdts E, Jonsson R, et al. Atherosclerosis in Sjögren’s syndrome: Evidence, possible mechanisms and knowledge gaps. Clin Exp Rheumatol. 2016;34(1):133–42.

Al-Awadhi AM, Olusi S, Hasan EA, Abdullah A. Serum concentrations of cardiac troponin-I in patients with rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren’s syndrome and Graves’ disease. Singapore Med J. 2007;48(9):847–9.

Ahlers MJ, Lowery BD, Farber-Eger E, et al. Heart failure risk associated with rheumatoid arthritis–related chronic inflammation. J Am Heart Assoc. 2020;9(10):e014661.

Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2016;76(1):17–28.

Aiewruengsurat D, Phongnarudech T, Liabsuetrakul T, Nilmoje T. Correlation of rheumatoid and cardiac biomarkers with cardiac anatomy and function in rheumatoid arthritis patients without clinically overt cardiovascular diseases: A cross-sectional study. IJC Hear Vasc. 2023;44:101161.

Sokolove J, Brennan MJ, Sharpe O, et al. Citrullination within the atherosclerotic plaque: A potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum. 2013;65(7):1719–24.

Borra SR, Panjiyar BK, Panicker SS, Danduboyina A. Role of cardiac biomarkers in the evaluation of rheumatoid arthritis: A systemic review. Cureus. 2023;15(10):e47416.

Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(1):76–80.

Lazzerini PE, Selvi E, Lorenzini S, et al. Homocysteine enhances cytokine production in cultured synoviocytes from rheumatoid arthritis patients. Clin Exp Rheumatol. 2006;24(4):387–93.

Czókolyová M, Pusztai A, Végh E, et al. Changes of metabolic biomarker levels upon one-year anti-tnf-α therapy in rheumatoid arthritis and ankylosing spondylitis: Associations with vascular pathophysiology. Biomolecules. 2021;11(10):1535.

Solomon DH, Demler O, Rist PM, et al. Biomarkers of cardiovascular risk in patients with rheumatoid arthritis: Results from the TARGET trial. J Am Heart Assoc. 2024;13(5):e032095.

Nam J, Onitsuka I, Hatch J, et al. Coronary veins determine the pattern of sympathetic innervation in the developing heart. Development. 2013;140(7):1475–85.

Fitzpatrick JK, Meyer CS, Schiller NB, et al. Ventricular-vascular coupling at rest and after exercise is associated with heart failure hospitalizations in patients with coronary artery disease. J Am Soc Echocardiogr. 2018;31(11):1212-1220.e3.

Södergren A, Karp K, Bengtsson C, et al. Wållberg-Jonsson S. Biomarkers associated with cardiovascular disease in patients with early rheumatoid arthritis. PLoS One. 2019;14(8):1–12.

Cuesta-López L, Escudero-Contreras A, Hanaee Y, et al. Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling. Front Immunol. 2024;15:1–13.

Ntusi NAB, Francis JM, Sever E, et al. Anti-TNF modulation reduces myocardial inflammation and improves cardiovascular function in systemic rheumatic diseases. Int J Cardiol. 2018;270:253–9.

Nguyen THP, Fagerland MW, Hollan I, et al. High-sensitivity cardiac troponin T is associated with disease activity in patients with inflammatory arthritis. PLoS One. 2023;18(2):e0281155.

Misra DP, Shenoy SN. Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk. Rheumatol Int. 2017;37(1):151–67.

Bhattad PB, Kulkarni M, Patel PD, Roumia M. Cardiovascular morbidity in ankylosing spondylitis: A focus on inflammatory cardiac disease. Cureus. 2022;14(6): e25633.

Sen R, Goyal A HJ. Seronegative spondyloarthropathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Hintenberger R, Affenzeller B, Vladychuk V, Pieringer H. Cardiovascular risk in axial spondyloarthritis - a systematic review. Clin Rheumatol. 2023;42(10):2621–33.

Forsblad-D’Elia H, Wallberg H, Klingberg E, et al. Cardiac conduction system abnormalities in ankylosing spondylitis: A cross-sectional study. BMC Musculoskelet Disord. 2013;14(1):237.

Arévalo M, López-Medina C, Moreno Martinez-Losa M, et al. Role of HLA-B27 in the comorbidities observed in axial spondyloarthritis: Data from COMOSPA. Jt Bone Spine. 2020;87(5):445–8.

Lorenzin M, Ometto F, Ortolan A, et al. An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. Ther Adv Musculoskelet Dis. 2020;12: 1759720X20934277.

Novikova DS, Korotaeva TJ, Loginova EJ, et al. Cinical implication of assessment of heart rate variability in patients with psoriatic arthritis. Terapevticheskii Arkhiv. 2009;81(6):47-52.

Achike O, Taiwo A, Nekkanti R, Marcu CB. Cardiac manifestations of seronegative spondyloarthropathy in a human leukocyte antigen B27–positive African American woman: A case report with literature review. Case (Phila). 2019;3(5):239–43.

Schwartz DM, Parel P, Li H, et al. PET/CT-based characterization of 18F-FDG uptake in various tissues reveals novel potential contributions to coronary artery disease in psoriatic arthritis. Front Immunol. 2022;13:909760.

Berg IJ, Van Der Heijde D, Dagfinrud H, et al. Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: A cross-sectional study. J Rheumatol. 2015;42(4):645–53.

Remuzgo-Martínez S, Rueda-Gotor J, Pulito-Cueto V, et al. Irisin as a novel biomarker of subclinical atherosclerosis, cardiovascular risk and severe disease in axial spondyloarthritis. Front Immunol. 2022;13:894171.

Pletikosic I, Marasovic Krstulovic D, Bakovic D, Susilovic Grabovac Z, Tandara L, Martinovic Kaliterna D. Association of inflammatory biomarkers and disease activity with subclinical myocardial dysfunction in psoriatic arthritis. Sci Rep. 2023;13(1):10371.

Caso F, Del Puente A, Oliviero F, et al. Metabolic syndrome in psoriatic arthritis: The interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol. 2018;37(3):579–86.

Markousis-Mavrogenis G, Nurmohamed MT, Koutsogeorgopoulou L, et al. Current understanding and future perspectives of brain–heart–kidney axis in psoriatic arthritis. Rheumatol Int. 2020;40(9):1361–8.

Conic RRZ, Damiani G, Schrom KP, et al. Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med. 2020;9(1):186.

Gravina AG, Dallio M, Masarone M, et al. Vascular endothelial dysfunction in inflammatory bowel diseases: Pharmacological and nonpharmacological targets. Oxid Med Cell Longev. 2018;2018:2568569.

Kruzliak P, Novák J, Novák M, Fodor GJ. Role of calprotectin in cardiometabolic diseases. Cytokine Growth Factor Rev. 2014;25(1):67–75.

Anindita B, Sugihartono T, Miftahussurur M, et al. High levels of fecal calprotectin and C-reactive protein in patients with colitis. J Med Life. 2023;16(1):48–51.

Bunu DM, Timofte CE, Ciocoiu M, et al. Cardiovascular manifestations of inflammatory bowel disease: Pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract. 2019;2019:3012509.

Nguyen THP, Fagerland MW, Deyab G, et al. Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis. PLoS One. 2021;16(6):e0253793.

Turkmen S, Askin L, Uzel KE, et al. Association of high-sensitivity troponin T with left ventricular dysfunction in ankylosing spondylitis. J Clin Rheumatol. 2020;26(3):87–93.

Colaco K, Lee KA, Akhtari S, et al. Association of cardiac biomarkers with cardiovascular outcomes in patients with psoriatic arthritis and psoriasis: A longitudinal cohort study. Arthritis Rheumatol. 2022;74(7):1184–92.

Chen F, Peng Y, Chen M. Diagnostic approach to cardiac involvement in idiopathic inflammatory myopathies: A strategy combining cardiac troponin I but not T assay with other methods. Int Heart J. 2018;59(2):256–62.

Jayakumar D, Zhang R, Wasserman A, Ash J. Cardiac manifestations in idiopathic inflammatory myopathies: An overview. Cardiol Rev. 2019;27(3):131–7.

Fairley JL, Wicks I, Peters S, Day J. Defining cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Rheumatol (United Kingdom). 2022;61(1):103–20.

Shah M, Shinjo SK, Day J, Gupta L. Cardiovascular manifestations in idiopathic inflammatory myopathies. Clin Rheumatol. 2023;42(10):2557–75.

Chung MP, Lovell J, Kelly W, et al. Myocarditis in patients with idiopathic inflammatory myopathies: Clinical presentation and outcomes. J Rheumatol. 2023;50(8):1039–46.

Bandeira M, Dourado E, Melo AT, et al. Predictors of cardiac involvement in idiopathic inflammatory myopathies. Front Immunol. 2023;14:1146817.

Hanisch F, Zierz S. C-reactive protein in idiopathic inflammatory myopathies. Myopain. 2015;23(1–2):45–51.

Miossi R, Souza FHC de, Shinjo SK. Could C-reactive protein and erythrocyte sedimentation rate support monitoring of dermatomyositis and polymyositis activity? MedicalExpress (São Paulo, online) [Internet]. 2017;4(2):M170205.

Tang Y, Du M, Qian W, et al. The diagnostic value of serum YKL-40 for myocardial involvement in idiopathic inflammatory myopathy. Clin Chim Acta. 2022;537:167–72.

Qiu M, Sun X, Qi X, et al. The diagnostic value of GDF-15 for myocardial involvement in idiopathic inflammatory myopathy. Rheumatol (United Kingdom). 2021;60(6):2826–33.

Lilleker JB, Roberts M, Diederichsen L. Cardiac involvement in inflammatory myopathies and inherited muscle diseases. Curr Opin Rheumatol. 2020;32(6):528–33.

Cunningham MW. Rheumatic fever, autoimmunity, and molecular mimicry: The streptococcal connection. Int Rev Immunol. 2014;33(4):314–29.

Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nat Rev Dis Prim. 2016;2:15084.

Martins TB, Hoffman JI, Augustine NH, et al. Comprehensive analysis of antibody responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol. 2008;20(3):445–52.

Tandon R, Sharma M, Chandrashekhar Y, et al. Revisiting the pathogenesis of rheumatic fever and carditis. Nat Rev Cardiol. 2013;10(3):171–7.

Saini N, Kumar D, Swarnim S, et al. Comparison of antistreptolysin O and anti-deoxyribonucleic B titers in healthy children to those with acute pharyngitis, acute rheumatic fever, and rheumatic heart disease aged 5-15 years. Ann Pediatr Cardiol. 2019;12(3):195–200.

Van Der Helm-Van Mil AH. Acute rheumatic fever and poststreptococcal reactive arthritis reconsidered. Curr Opin Rheumatol. 2010;22(4):437–42.

Szczygielska I, Hernik E, Kołodziejczyk B, et al. Rheumatic fever – New diagnostic criteria. Reumatologia. 2018;56(1):37–41.

Da Silva F, De Carvalho J. Rheumatic fever associated with antiphospholipid syndrome: Systematic review. J Immunol Res. 2014;2014:614591.

Arvind B, Ramakrishnan S. Rheumatic fever and rheumatic heart disease in children. Indian J Pediatr. 2020;87(4):305–11.

Attar A, Marzban P, Moaref A, Aghasadeghi K. The association of plasma high-sensitivity C-reactive protein level with rheumatic heart disease: The possible role of inflammation. Indian Heart J. 2018;70(3):346–9.

Pulimamidi VK, Murugesan V, Rajappa M, et al. Increased levels of markers of oxidative stress and inflammation in patients with rheumatic mitral stenosis predispose to left atrial thrombus formation. J Clin Diagnostic Res. 2013;7(11):2445–8.

Sukulal K, Mohanan Nair KK, Sasidharan B, et al. Implication of d-dimer in rheumatic severe mitral stenosis – A tertiary centre study. Indian Heart J. 2020;72(2):101–6.

Middleton FM, McGregor R, Webb RH, et al. Cytokine imbalance in acute rheumatic fever and rheumatic heart disease: Mechanisms and therapeutic implications. Autoimmun Rev. 2022;21(12):103209.

Kamblock Jo. Serum cardiac troponin I in acute rheumatic fever. Am J Cardiol. 2002;90(11):1277–8.

Ertug MH, Yilmaz GG, Akçurin G, et al. Can troponin T levels be useful in the diagnosis of rheumatic carditis. Ann Pediatr Cardiol. 2011;4(2):156–8.

Saunders R, Gunawijaya E, Hartawan INB, et al. Correlation of n-terminal pro-brain-type natriuretic peptide levels with the severity of single mitral regurgitation or accompanied by mild aorta valve dysfunction in patients with rheumatic heart disease in Sanglah general hospital. Cardiol Young. 2024;34(4):788–92.

Fischer K, Brzosko M. Significance of autoantibodies in diagnostics of systemic vasculitis. Explor Musculoskelet Dis. 2023;77–83.

Liori S, Samiotis E, Birba D, et al. Churg–Strauss syndrome-associated heart failure and left ventricular thrombosis. ESC Hear Fail. 2023;10(3):2107–12.

Ali AM, Yakupoglu HY, Fuchs TA, et al. Cardiac involvement in systemic and local vasculitides: The value of noninvasive multimodality imaging. Curr Probl Cardiol. 2023;48(8):101718.

Vats V, Patel K, Sharma DD, et al. Exploring cardiovascular manifestations in vasculitides: An in-depth review. Cureus. 2023;15(8):e44417.

Lin WC, Huang KC, Hsiung MC, Feng AN. Loeffler’s endocarditis in a patient with a new diagnosed Churg-Strauss syndrome (CSS): A case report. Casp J Intern Med. 2021;12(1):107–10.

Seo JS, Song JM, Kim DH, et al. A case of Loeffler’s endocarditis associated with Churg-Strauss Syndrome. J Cardiovasc Ultrasound. 2010;18(1):21.

Brucato A, Maestroni S, Masciocco G, et al. Il coinvolgimento cardiaco nella sindrome di Churg-Strauss. G Ital Cardiol. 2015;16(9):493-500.

Krall M, Gollmer J, Pollheimer MJ, et al. Myocardial infarction with non-obstructive coronary arteries in a patient double-seropositive for anti-glomerular basement membrane and anti-neutrophil cytoplasmic antibodies: A case report. Front Cardiovasc Med. 2022;9:893742.

Silva De Souza AW. Autoantibodies in systemic vasculitis. Front Immunol. 2015;6:184.

Cobilinschi CO, Grădinaru E, Săulescu I, et al. Refractory Takayasu’s arteritis with severe coronary involvement-Case report and literature review. J Clin Med. 2023;12(13):4394.

Idhrees M, Thilagavathi N, Bashir M, Velayudhan B V. Management of cardiac manifestations in Takayasu arteritis. Vessel Plus. 2020;4:23.

Jordan NP, Bezanahary H, D’Cruz DP. Increased risk of vascular complications in Takayasu’s arteritis patients with positive lupus anticoagulant. Scand J Rheumatol. 2015;44(3):211–4.

Carvajal Alegria G, Nicolas M, van Sleen Y. Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants? Front Immunol. 2023;14:1202160.

Zhao L li, Wang Y biao, Suo L. Meta-analysis of the risk factors for coronary artery lesion secondary to Kawasaki disease in Chinese children. Zhonghua Er Ke Za Zhi. 2011;49(6):459–67.

Chaudhary H, Nameirakpam J, Kumrah R, et al. Biomarkers for Kawasaki disease: Clinical utility and the challenges ahead. Front Pediatr. 2019;7:1–10.

Sato YZ, Molkara DP, Daniels LB, et al. Cardiovascular biomarkers in acute Kawasaki disease. Int J Cardiol. 2013;164(1):58–63.

Reindel R, Kim KYA, Baker SC, et al. Periostin is upregulated in coronary arteriopathy in Kawasaki Disease and is a potential diagnostic biomarker. Pediatr Infect Dis J. 2014;33(6):659–61.

Yu HR, Kuo HC, Huang EY, et al. Plasma clusterin levels in predicting the occurrence of coronary artery lesions in patients with kawasaki disease. Pediatr Cardiol. 2010;31(8):1151–6.

Yu X, Hirono KI, Ichida F, et al. Enhanced iNOS expression in leukocytes and circulating endothelial cells is associated with the progression of coronary artery lesions in acute Kawasaki Disease. Pediatr Res. 2004;55(4):688–94.

Yokouchi Y, Oharaseki T, Enomoto Y, et al. Expression of tenascin C in cardiovascular lesions of Kawasaki disease. Cardiovasc Pathol. 2019;38:25–30.

Yang S, Song R, Li X, et al. Thrombospondin-2 predicts response to treatment with intravenous immunoglobulin in children with Kawasaki disease. BMJ Paediatr Open. 2018;2(1):e000190.

Wang H, Zhang Y, Shen Z, et al. Comparing the effects of different management strategies on long-term outcomes for significant coronary stenosis in patients with Takayasu arteritis. Int J Cardiol. 2020;306:1–7.

Wang X, Dang A, Lv N, et al. Long-term outcomes of coronary artery bypass grafting versus percutaneous coronary intervention for Takayasu arteritis patients with coronary artery involvement. Semin Arthritis Rheum. 2017;47(2):247–52.

Pathadan AP, Tyagi S, Gupta MD, et al. The study of novel inflammatory markers in Takayasu arteritis and its correlation with disease activity. Indian Heart J. 2021;73(5):640–3.

Noel N, Butel N, Le Hoang P, et al. Small vessel involvement in Takayasu’s arteritis. Autoimmun Rev. 2013;12(3):355–62.

Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart. 2016;102(5):383–9.

Arias M, Heydari-Kamjani M, Kesselman MM. Giant cell arteritis and cardiac comorbidity. Cureus. 2021;13(2):e13391.

Wang Y, Li S, Tang S, et al. Risk factors of cardiovascular involvement in patients with Behcet’s disease. J Transl Autoimmun. 2023;6:100195.

Kim M, Kim K. Elevation of cardiac troponin I in the acute stage of Kawasaki disease. Pediatr Cardiol. 1999;20(3):184–8.

Yagmur J, Sener S, Acikgoz N, et al. Subclinical left ventricular dysfunction in Behcet’s disease assessed by two-dimensional speckle tracking echocardiography. Eur J Echocardiogr. 2011;12(7):536–41.

Lee GY, Jang SY, Ko SM, et al. Cardiovascular manifestations of Takayasu arteritis and their relationship to the disease activity: Analysis of 204 Korean patients at a single center. Int J Cardiol. 2012;159(1):14–20.

Kolluri N, Schmidt TJ, Elwazir MY, et al. Routine laboratory biomarkers as prognostic indicators of cardiac sarcoidosis outcomes. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG. 2022;39(3):e2022023.

Kraaijvanger R, Janssen Bonás M, Vorselaars ADM, Veltkamp M. Biomarkers in the diagnosis and prognosis of sarcoidosis: Current use and future prospects. Front Immunol. 2020;11:1–17.

Kiko T, Yoshihisa A, Kanno Y, et al. A multiple biomarker approach in patients with cardiac sarcoidosis. Int Heart J. 2018;59(5):996–1001.

Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev. 2013;18(6):733–46.

Yatsynovich Y, Dittoe N, Petrov M, Maroz N. Cardiac Sarcoidosis: A review of contemporary challenges in diagnosis and treatment. Am J Med Sci. 2018;355(2):113–25.

Caforio ALP, Baritussio A, Marcolongo R, et al. Serum anti‐heart and anti‐intercalated disk autoantibodies: Novel autoimmune markers in cardiac sarcoidosis. J Clin Med. 2021;10(11):2476.

Caforio A, Gianstefani S, Baritussio A, et al. Anti-heart and anti-intercalated disk autoantibodies: possible novel biomarkers of cardiac sarcoidosis. Eur Heart J. 2019;40(Suppl):679.

Lehtonen J, Uusitalo V, Pöyhönen P, et al. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J. 2023;44(17):1495–510.

Pour-Ghaz I, Kayali S, Abutineh I, et al. Cardiac sarcoidosis: pathophysiology, diagnosis, and management. Hearts. 2021;2(2):234–50.

Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol. 1998;82(4):537–40.

Mankad P, Mitchell B, Birnie D, Kron J. Cardiac Sarcoidosis. Curr Cardiol Rep. 2019;21(12):189–92.

Iannuzzi, MC, Rybicki, BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357(21):2153–65.

Ryland KL. Hepatic Sarcoidosis: Incidence, monitoring, and treatment. Clin Liver Dis. 2020;16(5):208–11.

Casanova N, Zhou T, Knox KS, Garcia JGN. Identifying novel biomarkers in sarcoidosis using genome-based approaches. Clin Chest Med. 2015;36(4):621–30.

Myoren T, Kobayashi S, Oda S, et al. An oxidative stress biomarker, urinary 8-hydroxy-2′-deoxyguanosine, predicts cardiovascular-related death after steroid therapy for patients with active cardiac sarcoidosis. Int J Cardiol. 2016;212:206–13.

Kobayashi S, Myoren T, Oda S, et al. Urinary 8-hydroxy-2′-deoxyguanosine as a novel biomarker of inflammatory activity in patients with cardiac sarcoidosis. Int J Cardiol. 2015;190(1):319–28.

Umei M, Akazawa H. MicroRNAs as biomarkers for cardiac sarcoidosis: No matter how small. J Cardiol. 2018;72(6):449–51.

Fujiwara W, Kato Y, Hayashi M, et al. Serum microRNA-126 and -223 as new-generation biomarkers for sarcoidosis in patients with heart failure. J Cardiol. 2018;72(6):452–7.

Quijano-Campos JC, Williams L, Agarwal S, et al. CASPA (CArdiac Sarcoidosis in PApworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: Protocol for a prospective observational cohort study. BMJ Open Respir Res. 2020;7(1):e000608.

Thi Hong Nguyen C, Kambe N, Kishimoto I, et al. Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement. J Dermatol. 2017;44(7):789–97.

Baba Y, Kubo T, Ochi Y, et al. High-sensitivity cardiac troponin T is a useful biomarker for predicting the prognosis of patients with systemic sarcoidosis regardless of cardiac involvement. Intern Med. 2023;62(21):3097–105.

Kandolin R, Lehtonen J, Airaksinen J, et al. Usefulness of cardiac troponins as markers of early treatment response in cardiac sarcoidosis. Am J Cardiol. 2015;116(6):960–4.

Baba Y, Kubo T, Kitaoka H, et al. Usefulness of high-sensitive cardiac troponin T for evaluating the activity of cardiac sarcoidosis. Int Heart J. 2012;53(5):287–92.